XML 39 R30.htm IDEA: XBRL DOCUMENT
v3.22.1

Description of Operations and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands | 3 Months Ended |
--- | --- | ---
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021
Description of Operations and Summary of Significant Accounting Policies |  |  |
Decrease to accumulated deficit | $ 37,200 |  |
Reduction to Additional Paid in Capital | 65,400 |  |
Equity and long-term investments | 544,437 |  | $ 483,845
Sale of equity investments managed by ISP FUND LP | 24,281 | $ 2,387 |
Purchase and sales of other investments managed by ISP Fund LP, net | 132,266 | (110,200) |
Purchases of equity investments managed by ISP Fund LP | (2,015) | (112,587) |
Increase in Deferred Tax Assets | 7,400 |  |
Prior Period Immaterial Correction |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |
Sale of equity investments managed by ISP FUND LP |  | 2,400 |
Purchase and sales of other investments managed by ISP Fund LP, net |  | 110,200 |
Purchases of equity investments managed by ISP Fund LP |  | $ (112,600) |
Convertible senior notes |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |
Increase in convertible notes | $ 35,600 |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |
Percentage of economic interest in any future payments made under the agreements | 15.00% |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |
Royalty rate for first level of annual global net sales (as a percent) | 15.00% |  |
Annual global sales level used to determine royalty rate | $ 3,000,000 |  |
Royalty rate for sales above first level of annual global net sales (as a percent) | 5.00% |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |
Royalty rate for combination products (as a percent) | 6.50% |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |
Royalty rate for combination products (as a percent) | 10.00% |  |

X
- Definition Represents the royalty rate for combination products. + References No definition available. + Details
Name: | inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. + References No definition available. + Details
Name: | inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Decrease to accumulated deficit. + References No definition available. + Details
Name: | inva_DecreaseToAccumulatedDeficit
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Increase in deferred tax assets. + References No definition available. + Details
Name: | inva_IncreaseInDeferredTaxAssets
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Increase to convertible notes. + References No definition available. + Details
Name: | inva_IncreaseToConvertibleNotes
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the percentage of economic interest in any future payments made under the agreements. + References No definition available. + Details
Name: | inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchase and sale of other investments managed by ISP FUND LP + References No definition available. + Details
Name: | inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reduction to additional paid in capital + References No definition available. + Details
Name: | inva_ReductionToAdditionalPaidInCapital
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sale of equity investments managed by ISP FUND LP + References No definition available. + Details
Name: | inva_SaleOfEquityInvestmentsManagedByIspFundLp
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | inva_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | inva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_LongTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash (inflow) outflow from investing activities classified as other. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585 + Details
Name: | us-gaap_PaymentsForProceedsFromOtherInvestingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_SeniorUnsecuredConvertibleNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |